With the goal of reducing the dramatic gap between how nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are currently screened, diagnosed, and managed, AACE released at its 2022 Annual Meeting in May, the new AACE Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings co-sponsored by the American Association for Study of Liver Diseases (AASLD).

To ensure that endocrinologists, gastroenterologists, hepatologists, primary care physicians, and all other HCPs, who are in a position to identify and care for patients at risk of developing NAFLD and/or NASH, are familiar with this guideline, clinicians require education about how to implement current AACE recommendations in their practice and thus identify patients early to prevent the development of liver fibrosis progression to cirrhosis, and comorbidities.

Physicians and Physician Assistants

The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.

Nurses

American Association of Clinical Endocrinology is approved by the California Board of Registered Nursing, Provider Number 17762, for 3 contact hours.

Upon successful completion of the program, participants should be better able to: 

• Identify the diagnosis and management of NAFLD and NASH as the hepatic manifestation of the metabolic syndrome.
• Describe noninvasive tests currently used and in development for identifying patients with NAFLD and NASH, and those at high risk for clinically significant liver fibrosis.
• Review the efficacy of various treatments for NAFLD and NASH, including pharmacotherapy such as GLP-1 RA.
• Apply the latest management recommendations in clinical practice from the AACE Clinical Practice Guideline on NAFLD and NASH.

The target audience for this activity is intended for HCPs involved in treating patients with NASH/NAFLD, including endocrinologists, gastroenterologists, hepatologists, primary care physicians, and advanced practice professionals (nurse practitioners, physician assistants, etc.

 

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. 

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  

Planners

• Diana Barb, MD, Clinical Associate Professor, University of Florida, Gainesville, Florida   
  No relevant financial relationships  
• Kenneth Cusi, MD, FACE, FACP, Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida   
  Disclosures: Consultant: Allergan Pharmaceuticals, AstraZeneca, Axcella, Bristol Myers Squibb, Boehringer Ingelheim, Cirius, Coherus, Deuterex, Echosens, Eli Lilly, Fractyl, Genentech, Genfit, Madrigal, Merck, Novo Nordisk, Prosciento, Zydus 
  Grant/Research Support: Inventiva, National Institutes of Health, Echosens, Inventiva, National Institutes of Health, Novo Nordisk, Zydus,Nordic  
• Scott Isaacs, MD, FACE, FACP, Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia  
  No relevant financial relationships  
• Sangeeta Kashyap, MD, Professor of Medicine Cleveland Clinic Lerner College of Medicine, Associate Program Director for Endocrinology, Diabetes and Metabolism Fellowship, Associate Editor of Journal of Clinical Endocrinology and Metabolism 
  Disclsoures: Chair of medication committee for GI Dynamics endobarrier trial 

Faculty

• Kenneth Cusi, MD, FACE, FACP, Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida   
  Disclosures: Consultant: Allergan Pharmaceuticals, AstraZeneca, Axcella, Bristol Myers Squibb, Boehringer Ingelheim, Cirius, Coherus, Deuterex, Echosens, Eli Lilly, Fractyl, Genentech, Genfit, Madrigal, Merck, Novo Nordisk, Prosciento, Zydus 
  Grant/Research Support: Inventiva, National Institutes of Health, Echosens, Inventiva, National Institutes of Health, Novo Nordisk, Zydus,Nordic  

• Romina Lomonaco, MD, assistant professor of medicine, Division of Endocrinology, Diabetes and Metabolism, The University of Florida, Gainesville, Florida 

  Disclosures: No relevant financial relationships 

   
• Sangeeta Kashyap, MD, Professor of Medicine Cleveland Clinic Lerner College of Medicine, Associate Program Director for Endocrinology, Diabetes and Metabolism Fellowship, Associate Editor of Journal of Clinical Endocrinology and Metabolism  
  Disclsoures: Chair of medication committee for GI Dynamics endobarrier trial 
• Zobair M. Younossi MD, MPH, FACP, FACG, AGAF, FAASLD, President, Inova Medicine Services, Chairman, Clinical Research, Inova Health System, Professor and Chairman, Department of Medicine, Inova Fairfax Medical Campus   
  Disclosures: NovoNordisk Consultant

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.

This activity is supported by an independent educational grant from: Novo Nordisk.

4

4

FREE

https://my.aace.com/productdetails?id=a1B5a00000jumxUEAQ

PCP, NP, PA, EDUCATOR, ENDO